Avastin Duration Of Use In NSCLC May Increase Alongside Promotional Efforts
Executive Summary
Duration of use for Avastin in lung cancer may increase with continued promotion of the indication, according to Genentech
You may also be interested in...
Lucentis Faces Additional Pressure From NIH’s Avastin Trials
Genentech could face difficulties enrolling trials for its ocular vascular endothelial growth factor inhibitor Lucentis due to pressure from NIH-sponsored trials of the firm's oncologic VEGF inhibitor Avastin
Lucentis Faces Additional Pressure From NIH’s Avastin Trials
Genentech could face difficulties enrolling trials for its ocular vascular endothelial growth factor inhibitor Lucentis due to pressure from NIH-sponsored trials of the firm's oncologic VEGF inhibitor Avastin
Biogen/Elan Begin Promoting Tysabri Efficacy; Other JP Morgan Items In Brief
Tysabri marketing moves to efficacy: Biogen Idec/Elan are returning the marketing emphasis for the multiple sclerosis drug Tysabri (natalizumab) back to efficacy, after initially focusing on educating patients and physicians about the TOUCH risk management program and the risk of progressive multifocal leukoencephalopathy, Biogen Idec CEO Jim Mullen states. "It's been probably since we withdrew this product from the market in February 2005 [that] we've really discussed efficacy," he said. "That's the next phase of this launch, to really emphasize the important efficacy of this product." The firms relaunched Tysabri in June following FDA reapproval (1"The Pink Sheet" June 12, 2006, p. 5)...